Home ›

Publications

Filters: Author is del Rio, E  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
M
Marcuello E, Páez D, Paré L, Salazar J, Sebio A, del Rio E, et al. A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. British journal of cancer. 2011;105(1):53-7. Abstract
P
Páez D, Paré L, Altés A, Sancho-Poch FJ, Petriz L, Garriga J, et al. Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil. Journal of cancer research and clinical oncology. 2010;136(11):1681-9. Abstract
Páez D, Salazar J, Paré L, Pertriz L, Targarona E, del Rio E, et al. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes. International journal of radiation oncology, biology, physics. 2011;81(5):1319-27. Abstract
Paez D, Paré L, Espinosa I, Salazar J, del Rio E, Barnadas A, et al. Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy? Cancer science. 2010;101(9):2048-53. Abstract
Paré L, Paez D, Salazar J, del Rio E, Tizzano E, Marcuello E, et al. Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy. British journal of clinical pharmacology. 2010;70(2):268-72. Abstract
Paré L, Salazar J, del Rio E, Baiget M, Altés A, Marcuello E, et al. Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy in females. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(20):3468; author reply 3468-9.
R
Ramón y Cajal T, Altés A, Paré L, del Rio E, Alonso C, Barnadas A, et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast cancer research and treatment. 2010;119(1):33-8. Abstract